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Abstract
Background: The adaptor protein PINCH is overexpressed in the stroma of several types of cancer, and is an
independent prognostic marker in colorectal cancer. In this study we further investigate the relationship of PINCH
and survival regarding the response to chemotherapy in colorectal cancer.
Results: Paraffin-embedded tissue sections from 251 primary adenocarcinomas, 149 samples of adjacent normal
mucosa, 57 samples of distant normal mucosa and 75 lymph node metastases were used for
immunohistochemical staining. Stromal staining for PINCH increased from normal mucosa to primary tumour to
metastasis. Strong staining in adjacent normal mucosa was related to worse survival independently of sex, age,
tumour location, differentiation and stage (p = 0.044, HR, 1.60, 95% CI, 1.01-2.52). PINCH staining at the invasive
margin tended to be related to survival (p = 0.051). In poorly differentiated tumours PINCH staining at the invasive
margin was related to survival independently of sex, age and stage (p = 0.013, HR, 1.90, 95% CI, 1.14-3.16), while in
better differentiated tumours it was not. In patients with weak staining, adjuvant chemotherapy was related to
survival (p = 0.010, 0.013 and 0.013 in entire tumour area, invasive margin and inner tumour area, respectively), but
not in patients with strong staining. However, in the multivariate analysis no such relationship was seen.
Conclusions: PINCH staining in normal adjacent mucosa was related to survival. Further, PINCH staining at the
tumour invasive margin was related to survival in poorly differentiated tumours but not in better differentiated
tumours, indicating that the impact of PINCH on prognosis was dependent on differentiation status.
Background
PINCH, particularly interesting new cystein-histidine-
rich protein, was first identified in 1994 as an evolution-
ary conserved protein belonging to the LIM family, con-
sisting of five LIM domains [1]. A LIM domain
mediates protein interactions and consists of a protein-
binding motif with a specific three-dimensional struc-
t u r ec o m p r i s i n gad o u b l ez i n cf i n g e r[ 2 ] .T h eP I N C H
gene is located to chromosome 2q12.2 and encodes a
protein that functions as an adaptor protein [3]. PINCH
is known to directly associate with two proteins: integ-
rin-linked kinase (ILK) [4] and Nck-2 [5]. ILK is an
intracellular serine/threonine protein kinase that is a
constituent of integrin-mediated cell-matrix focal adhe-
sions, structures that mediate cell adhesion and signal
transduction between the extracellular matrix and the
intracellular compartment [6]. Nck-2 is an adaptor
protein capable of recognizing several key components
of growth factor receptor kinase-signalling pathways [5].
PINCH binds Nck-2 and ILK by means of two separate
LIM domains, LIM1 for ILK [4] and LIM4 for Nck-2
[5], and forms a multiprotein complex with these two
proteins [4]. Thus, PINCH could provide a connection
between the growth factor receptor and integrin-signal-
ling pathways by mediating the interaction between
Nck-2 and ILK.
The tumour-associated stroma is important in facili-
tating cancer growth and invasion, and PINCH expres-
sion has been shown to be up-regulated in tumour-
associated stroma of several common cancer types, espe-
cially at the tumour invasive margin [7]. This indicates
that PINCH could be involved in tumour progression.
Further, PINCH functions in the integrin and growth
factor signalling pathways, both important mediators of
the tumour-stromal interaction. In concordance with
the theory of PINCH promoting tumour progression, it
has been shown that a high stromal expression of
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worse prognosis in colorectal cancer [8].
I nt h i ss t u d yw ef u r t h e ri n v e stigated the relationship
of PINCH expression with survival and clinicopathologi-
cal variables in colorectal cancer patients and found that
PINCH expression at the tumour invasive margin or
adjacent normal mucosa is independently related to
prognosis. We also studied the effect of PINCH expres-
sion on outcome of adjuvant chemotherapy, and found
that high PINCH expression could be related to treat-
ment outcome. However, we did not find it to be an
independent marker.
Methods
Patients
This study included 251 randomly selected patients
with primary colorectal adenocarcinoma. The charac-
teristics of the patients and tumours were obtained
from surgical and pathological records at Linköping
and Vrinnevi hospitals. The median age of the patients
was 69 years (range 25-94 years). Tumour differentia-
tion was graded as good, moderate, poor, or mucinous
(including signet-ring cell carcinomas), and inflamma-
tory infiltration was graded as weak, moderate or
strong. Necrosis was graded as <10% and ≥ 10%. All
patients underwent surgical resection at Linköping
University Hospital (Linköping, Sweden) or Vrinnevi
Hospital (Norrköping, Sweden), during the time period
of 1973 to 2001. After surgery the patients were con-
sidered to have adjuvant chemotherapy, which was
given to 27 patients. The main indication for adjuvant
treatment was radically resected stage II or III tumours
with additional risk factors (i.e. vascular invasion and
poor differentiation) in colon cancer. Also, one rectal
cancer patient with a stage III tumour and additional
risk factors was included. Depending on various
study protocols active at each time, the drugs and
administration schedule differed (Table 1). The study
was approved by the local human research ethics
committee.
Immunohistochemistry
For immunohistochemical staining 5 μmf o r m a l i n -
fixed, paraffin-embedded tissue sections were used.
The study included 251 samples of primary tumour,
among them, 149 had adjacent normal mucosa. There
were also 57 samples of distant normal mucosa taken
from the margin of the distant resection and 75 sam-
ples of regional lymph node metastasis. The sections
were incubated at 60 oC overnight, then deparaffinized
in xylene and rehydrated in a series of ethanol with
decreasing concentrations. In order to expose masked
epitopes the sections were boiled in 0.01 M Tris-EDTA
buffer (pH 9.0) in a high pressure cooker at 125 oC for
30 seconds after which the sections were cooled to 90
oC for 10 seconds and then kept in room temperature
for 10 minutes. After washing in phosphate buffered
saline (PBS, pH 7.4) the sections were incubated in a
2% H2O2- methanol solution for 20 minutes in order
to block endogenous peroxidase activity. The sections
were then washed in PBS and incubated with protein
block solution (Dako, Carpinteria, CA) for 10 minutes.
Subsequently, the sections were incubated with the pri-
mary antibody, a polyclonal rabbit anti-PINCH (Rock-
land Laboratories, Gilbertsville, PA) (2 μg/ml), for 1
hour. After washing in PBS, the sections were incu-
bated with the secondary antibody (Dako ChemMate
EnVision Detection Kit; Dako, Glostrup, Denmark), a
goat anti- rabbit/mouse polymeric HRP conjugate for
25 minutes, followed by washing with PBS. The peroxi-
dase reaction was performed using 3,3’- diaminobenzi-
dine chromogen (Dako) and finally the sections were
counterstained with haematoxylin. Sections known to
stain positively were used as positive controls. For the
negative control, PBS was used instead of the primary
antibody.
The sections were microscopically examined and
scored independently by two investigators without any
knowledge of the clinicopathological data. The staining
intensity was determined for distant and adjacent nor-
mal mucosa, the entire tumour area, the inner tumour
area, and the invasive margin of the tumours, and was
scored as negative, weak, moderate or strong. Because
of the clinicopathological similarities we combined the
negatively, weakly and moderately stained groups as one
group (weak group), and compared it to the strong
group in the statistical analysis. The cases with discre-
pant scoring were re-evaluated individually until both
investigators agreed on the scoring. The remaining were
re-examined by the two investigators together using a
dual-headed microscope in order to reach a consensus
score. To avoid artificial effects, areas with necrosis,
Table 1 Status of adjuvant therapy in colorectal cancer
patients
Adjuvant therapy N
5-Fluorouracil (5-FU)+ leukovorin (Nord) 8
Panorex 6
Xeloda 5
5-FU + leukovorin (Mayo) 5
Fluorouracil + levamisole 1
Panorex + 5-FU + leukovorin (Mayo) 1
Other chemotherapy 1
Radiotherapy 1
Unknown 1
Nord and Mayo: administration schedules. Nord: drugs are administered as
injections on day 1 and 2. Mayo: drugs are administered as injections on
day 1-5.
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were not considered.
Statistical analysis
The statistical analyses were performed using SPSS ver-
sion 17.0. The c2 test was used to determine differences
in PINCH expression among normal mucosa, primary
and metastatic colorectal cancer, as well as relationship
of PINCH expression in primary colorectal cancer with
clinicopathological variables. Cox’s proportional hazard
model was used to test relationship between PINCH
expression and patients’ survival. The Kaplan- Meier
method was used to calculate survival curves. Two-
sided p-values of <0.05 were considered statistically
significant.
Results
PINCH expression in normal mucosa, primary tumour and
metastasis
PINCH staining was present in the cytoplasm of the
fibroblasts in the stroma, whereas normal epithelial and
tumour cells, except for two cases, did not show any
staining (Figure 1). Of the 57 distant normal mucosa
samples, 61% were weakly stained and 39% were
strongly stained. As for the 149 adjacent normal
mucosa samples, 71% were weakly stained, and 29% of
the samples were strongly stained. Of the 251 primary
tumour samples 46% had weak staining and 54% strong
staining, and of 75 metastases, 20% were weakly stained,
and 80% strongly stained. The frequency of the strong
PINCH staining was shown to be significantly increased
from adjacent normal mucosa to primary tumour (p =
0.0001), and from primary tumour to metastasis (p =
0.007) (Figure 2). The intensity of PINCH staining did
not significantly differ between distant normal and adja-
cent normal mucosa (p = 0.077), nor between distant
normal mucosa and primary tumour (p = 0.16).
PINCH expression in relation to patient survival and other
clinicopathological variables
In adjacent normal mucosa, strong stromal staining for
PINCH was related to poorer survival (p = 0.0008,
Figure 3). In the multivariate analysis the relationship
was still significant independently of sex, age, tumour
location, differentiation and stage (p = 0.044, HR, 1.60,
95% CI, 1.01-2.52, Table 2). Strong PINCH staining at
the primary tumour invasive margin also tended,
although not significantly, to be related to worse survival
(p = 0.051). Furthermore, in poorly differentiated
tumours (including mucinous and signet-ring cell carci-
nomas), the strong staining at the invasive margin was
significantly related to worse survival both in the univar-
ite analysis (p = 0.001, Figure 4A), and in the multivari-
ate analysis including sex, age and stage (p = 0.013, HR,
Figure 1 Immunohistochemical staining for PINCH. A) Weak PINCH immunohistochemical staining (yellow-brown colour) in distant normal
mucosa. B) Moderate staining in the adjacent normal mucosa (top right corner of the picture) and strong staining in the primary tumour (lower
left of the picture). C) Even stronger staining in lymph node metastasis.
Figure 2 PINCH expression in distant and adjacent normal
mucosa, primary tumour and lymph node metastasis. The
frequency of the strong PINCH expression is significantly increased
from adjacent normal mucosa to primary tumour (p = 0.0001) and
from primary tumour to metastasis (p = 0.007).
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ferentiated tumours (including well and moderately dif-
ferentiated tumours) PINCH staining was not related to
survival (p = 0.40, Figure 4B). Strong PINCH staining at
the tumour invasive margin was also related to less
Figure 3 PINCH expression in adjacent normal mucosa in
relation to patient survival. Strong expression of PINCH in
adjacent normal mucosa is significantly related to worse survival
(p = 0.0008).
Table 2 Cox multivariate regression analysis of PINCH
expression in adjacent normal mucosa, sex, age, tumour
location, grade of differentiation and stage in relation to
patient survival in colorectal cancer
Variable N (%) Death
(%)
HR 95% CI P-
value
PINCH expression
Weak 102
(70)
52 (51) 1.00 - -
Strong 44 (30) 35 (80) 1.60 1.01-2.53 0.044
Sex
Male 83 (57) 52 (63) 1.00 - -
Female 63 (43) 35 (56) 0.82 0.53-1.28 0.39
Age (years)
≤ 69 70 (48) 46 (66) 1.00 - -
> 69 76 (52) 41 (53) 1.51 0.96-2.39 0.075
Tumour Location
Colon 77 (53) 46 (60) 1.00 - -
Rectum 69 (47) 41 (59) 1.16 0.75-1.79 0.51
Differentiation
Well+moderate
+poor
121
(83)
71 (59) 1.00 - -
Mucinous 25 (17) 16 (64) 0.95 0.55-1.65 0.85
Stage
I 17 (12) 3 (18) 1.00 - -
II 34 (23) 15 (44) 3.32 0.95-11.62 0.061
III 64 (44) 40 (63) 6.98 2.11-23.06 0.0014
IV 31 (21) 29 (94) 28.71 8.24-
100.03
<
0.0001
HR: Hazard ratio; 95% CI: 95% confidence interval. (69 years = median age at
operation).
Figure 4 PINCH expression at the primary tumour invasive
margin in relation to patient survival. A) Poorly differentiated
tumours. B) Better differentiated tumours. Strong expression of
PINCH is related to worse survival in poorly differentiated tumours
(p = 0.001) but not in better differentiated tumours (p = 0.40).
Table 3 Cox multivariate regression analysis of PINCH
expression at tumour invasive margin, sex, age and
stage in poorly differentiated tumours in relation to
patient survival in colorectal cancer
Variable N (%) Death (%) HR 95% CI P-value
PINCH expression
Weak 50 (55) 30 (60) 1.00 - -
Strong 41 (45) 36 (88) 1.90 1.14-3.16 0.013
Sex
Male 48 (53) 34 (71) 1.00 - -
Female 43 (47) 32 (74) 1.10 0.67-1.81 0.69
Age (years)
≤ 69 51 (56) 40 (78) 1.00 - -
> 69 40 (44) 26 (65) 1.37 0.81-2.32 0.24
Stage
I+II 18 (20) 7 (39) 1.00 - -
III 38 (42) 26 (68) 2.75 1.16-6.56 0.022
IV 35 (38) 33 (94) 9.09 3.63-22.75 < 0.0001
HR: Hazard ratio; 95% CI: 95% confidence interval. (69 years = median age at
operation).
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differentiation (p = 0.005, Table 4).
PINCH expression in relation to chemotherapy
In the univariate analysis, patients with weak stromal
staining for PINCH in the entire primary tumour (p =
0.010), inner tumour area (p = 0.013) or at the invasive
margin (p = 0.013) receiving adjuvant chemotherapy
had significantly better survival than those without che-
motherapy. In patients with strong staining for PINCH
in the entire tumour (p = 0.13), inner tumour area (p =
0.16) or at the invasive margin (p = 0.16) chemotherapy
was not related to survival. However, in the multivariate
analysis there was no significant relationship between
PINCH staining and chemotherapy outcome (data
unshown).
Discussion
Predictive and prognostic markers in colorectal cancer
patients have been the subject of intense research. The
determination of prognosis predominantly relies on the
histopathological examination, although there are cer-
tainly other factors influencing survival. Approaches are
being made to improve prognostic methods, including
analyzing additional histopathological factors and mole-
cular and genetical markers. Although these markers are
promising they are not yet routinely used. Potential
markers include, for example, allelic imbalances, chro-
mosomal instability, expression of oncogenes, loss of
tumour suppressor genes, markers of proliferation,
angiogenesis, inflammation and cell adhesion as
well as genes involved in the response to chemo- and
radiotherapy.
In this study we have shown that the intensity of stro-
mal immunohistochemical staining for PINCH was
increased from normal mucosa to primary tumour and
from primary tumour to lymph node metastasis in col-
orectal cancer. We have also shown that strong staining
for PINCH in normal adjacent mucosa was related to
worse survival. Furthermore, in poorly differentiated
tumours, PINCH staining at the tumour invasive margin
was significantly related to survival, while in better dif-
ferentiated tumours it was not. The pattern of PINCH
staining increasing from normal tissue to tumour and
from tumour to metastasis has been seen in previous
studies [8] and indicates that PINCH is involved in
tumour progression and invasion. PINCH up-regulation
in the stroma of oral squamos cell carcinoma also pre-
dicts lymph node metastasis, further implicating PINCH
in invasion and metastasis [9]. It has previously been
shown that PINCH staining at the tumour invasive mar-
gin is an independent prognostic marker in colorectal
cancer [8], which we have also seen a tendency towards
in the current study. This further supports the idea that
PINCH, through involvement in the tumour-stromal
interaction, promotes tumour invasiveness. The finding
that the intensity of PINCH staining in poorly differen-
tiated tumours was significantly related to survival while
in better differentiated tumours it was not suggests that
the effect of PINCH expression on the aggressiveness of
the tumour could be dependent on differentiation status.
It seems as the impact of PINCH expression on survival
is limited in well differentiated tumours. As it has pre-
v i o u s l yb e e ns e e n[ 8 ] ,w ea l s of o u n ds t r o n gP I N C H
expression to be related to better differentiation. Poor
differentiation is correlated to worse survival [10], never-
theless strong expression of PINCH at the tumour inva-
sive margin seems to be related to a worse prognosis.
Further, PINCH staining in the adjacent normal mucosa
was found to be related to survival, which has not been
reported previously. Although histologically the mucosa
adjacent to a tumour appears normal, it is from colorec-
tal cancer patients and may differ biologically from the
normal mucosa of a healthy individual. Because of the
proximity of the adjacent normal mucosa with the inva-
sive margin of the tumour, it is possible that this see-
mingly normal tissue is already involved in signalling
Table 4 Intensity of PINCH expression at the primary
tumour invasive margin in relation to clinicopathological
variables
Variable PINCH expression at tumour invasive margin
Weak (%) Strong (%) P-value
Sex 0.97
Male 55 (53) 74 (54)
Female 48 (47) 64 (46)
Age (years) 0.97
≤ 69 52 (50) 70 (51)
> 69 51 (50) 68 (49)
Tumour location 0.28
Colon 63 (62) 75 (55)
Rectum 39 (38) 62 (45)
Stage 0.34
I 13 (13) 9 (7)
II 22 (21) 28 (21)
III 44 (43) 56 (42)
IV 24 (23) 41 (31)
Differentiation 0.005
Better 53 (52) 95 (69)
Poorer 50 (48) 42 (30)
Inflammatory infiltration 0.047
Weak 25 (26) 54 (40)
Moderate 43 (44) 52 (39)
Strong 30 (31) 28 (21)
Necrosis 0.32
< 10% 58 (59) 70 (53)
≥ 10% 40 (41) 63 (47)
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PINCH expression in the adjacent normal mucosa is
related to survival implicates PINCH in the biological
changes occurring in the mucosa around a tumour.
The interaction between tumour and stroma has been
recognized as an important factor influencing tumour
growth and progression [11,12]. PINCH is involved in
several signalling pathways important to the tumour-
stromal interaction by functioning as an adaptor protein
in the integrin- and growth factor signalling pathways
[5,13]. Loss of PINCH in c. elegans results in a pheno-
type identical to integrin null mutants [3], indicating
that PINCH is required for integrin signalling, one of
the key components in the cell-stromal interaction.
Integrin-mediated adhesion to the extracellular matrix
results in the stimulation of various intracellular path-
ways important in the regulation of cell attachment,
migration, proliferation [14,15], survival and apoptosis
[16]. PINCH directly associates with the proteins integ-
rin-linked kinase (ILK) and Nck-2, and assembly of the
multi-protein complex containing PINCH, ILK and
Nck-2 prevents the proteolytic degradation of the pro-
teins that are part of the complex [13]. Therefore, an
increase in PINCH expression will increase the stability
of the other proteins in the complex, thus increasing
ILK and Nck-2 signalling. Possibly, the aggressive beha-
viour of tumours with a high stromal expression of
PINCH can be explained by an up-regulation of the sig-
nalling pathways that are dependent on the adaptor
function of PINCH. It is not clear which factors during
tumour progression that influence the expression of
PINCH itself. Studies of epithelial-to-mesenchymal tran-
sition (EMT) in renal tubuli have shown PINCH mRNA
expression to be increased in response to transforming
growth factor (TGF)-b1 [17], a known inducer of EMT
in several biological systems, including renal tubuli [18].
TGF-b1 has been implicated in the progression of color-
ectal cancer [19]; therefore it is possible that TGF-b1
could be involved in the regulation of PINCH in color-
ectal tumours.
ILK is a serine/threonine protein kinase that associates
with the cytoplasmic domain of the integrin b1a n db3
subunits, thereby regulating integrin mediated signal
transduction [6]. PINCH and ILK have been shown to
be indispensable for proper control of cell shape change,
motility and survival [13]. ILK is activated through the
PI3K-signalling pathway and functions in cell survival by
regulating the PKB/Akt signalling pathway [20]. Up-reg-
ulation of ILK in tumour cells is observed in several
types of cancer, and is associated with tumour stage,
metastasis and worse prognosis [21-23]. ILK overexpres-
sion promotes an invasive phenotype, induces in vivo
tumourigenesis [24], anchorage independent cell growth
[6] and anchorage independent cell cycle progression
[25]. Clearly, ILK plays an oncogenic role when overex-
pressed in epithelial cells. However, in our study we
found PINCH to be overexpressed in the stroma, there-
fore ILK signalling may be increased in stromal cells.
The question is therefore how increased ILK signalling
in stromal cells can influence the aggressiveness of the
tumour.
The fibroblasts of the tumour associated stroma can
affect tumour development by secreting soluble factors
such as vascular endothelial growth factor (VEGF) [26]
and matrix metalloproteinases (MMP:s) [27]. ILK contri-
butes to tumour progression by increasing the expres-
sion of VEGF via the activation of PKB/Akt and HIF-
1a, thereby stimulating angiogenesis [28]. Angiogenesis
i sap r e r e q u i s i t ef o rt u m o u rg r o w t ha n dp r o g r e s s i o n
[29], and the levels of angiogenetic factors such as
VEGF are related to prognosis in several types of cancer,
including colorectal cancer [30]. Angiogenesis is specu-
lated to contribute to metastasis by increasing the num-
ber of leaky vessels into which the tumour cells can
intravasate [31] and the VEGF expression has been
shown to be related to tumour stage [32], lymph node
metastasis [33,34], distant metastasis [34] and depth of
tumour invasion [32]. Furthermore, at our laboratory, a
recent study (unpublished data) of rectal cancer patients
showed that PINCH expression was related to blood-
and lymph vessel density, implicating PINCH as a regu-
lator of angiogenesis.
Further contributing to an invasive phenotype, ILK
overexpression stimulates the expression of matrix
metalloproteinase -9 (MMP-9) [35]. Metalloproteinases
are zinc-dependent endopeptidases that degrade compo-
nents of the extracellular matrix [36], a process that is
necessary for angiogenesis, tumour invasion and metas-
tasis to occur [37]. Increased expression of MMP:s is
associated with tumour invasion [38,39] and metastasis
[40,41]. In particular, MMP-9 plays a key role in the
degradation of several components of the ECM, includ-
ing type IV, V and XI collagen, gelatin and laminin [42],
and has been found to be over-expressed in several
types of cancer and to be associated with a worse prog-
nosis [43,44].
Remodelling of the extracellular matrix is a necessary
process in order for a tumour to grow and progress [45].
The remodelling consists not only of the breakdown of
ECM, but also the neosynthesis of certain ECM compo-
nents such as fibronectin [46]. Assembly of fibronectin is
regulated by ILK in a process requiring PINCH [24].
Therefore, an increase in PINCH expression at the
tumour invasive margin could be associated with
enhanced assembly of fibronectin matrix. Since the fibro-
nectin matrix has a major impact on cell adhesion,
migration, and cell growth [47,48], an increased assembly
could stimulate the migratory and invasive capacity of
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tumour stroma has been found to be correlated to lymph
node metastasis, proliferation and worse survival [49].
The interaction between fibronectin and tumour cells
activates various signalling pathways involved in tumour
progression, leading for example to the increased expres-
sion of metalloproteinases MMP-2 and -9 [50,51].
ILK is connected to the growth factor signalling path-
ways through PINCH, since PINCH forms a multiprotein
complex with ILK and the adaptor protein Nck-2 [5].
Nck-2 recognizes several key components of growth factor
receptor kinase-signalling pathways, including EGF recep-
tors, PDGF receptor-b and insulin receptor substrate-1
(IRS-1) [5]. Thus, PINCH provides a physical connection
between the growth factor receptor-signalling pathways
and the integrin-mediated pathways by connecting ILK
and the integrins with EGF-and PDGF receptors and IRS-
1 [4]. Through the complex formation with Nck-2,
increased PINCH expression may be associated with an
up-regulation of the growth factor signalling pathways.
Growth factors are important regulators of the tumour-
stromal interaction, and for some carcinomas an increase
in growth factor receptors in stromal cells is thought to be
an essential part in tumour to stroma signalling and hence
tumour growth and progression [52,53].
Since PINCH expression is related to tumour progres-
sion and prognosis, we were interested in investigating
whether PINCH was also related to response to treat-
ment. In our group of patients, 27 patients received
adjuvant chemotherapy. In the univariate analysis we
found chemotherapy to be significantly related to survi-
val in patients with weak stromal staining for PINCH at
the invasive margin, while in patients with strong stain-
ing there was no relationship between chemotherapy
and survival. This indicates that PINCH could be one
factor influencing the outcome of adjuvant chemother-
a p y .H o w e v e r ,i nt h em u l t i v a r i a t ea n a l y s i sw ef o u n dn o
significant correlation between chemotherapy outcome
and PINCH expression. Possibly, this could be due to
the relationship of PINCH expression with inflammatory
infiltration and differentiation grade, known prognostic
factors in colorectal cancer [10,54]. Further, the rela-
tively low number of patients may contribute to the lack
of significant results. More results would require a pro-
spective setting; as with many studies of prognostic or
predictive markers the major weakness of this study is
the use of retrospective, non-randomized material as
well as the low number of the patients.
Conclusions
Stromal immunohistochemical staining for PINCH in
normal mucosa adjacent to a tumour was found to be
related to survival in colorectal cancer patients.
Although appearing histologically normal, biological
changes may occur in the mucosa near a tumour, possi-
bly affecting the behaviour of the tumour. Further,
PINCH staining at the tumour invasive margin was
related to survival in poorly differentiated tumours but
not in better differentiated tumours, indicating that the
impact of PINCH on prognosis is dependent on differ-
entiation status. Regarding treatment, adjuvant che-
motherapy was significantly related to survival in
patients with weak stromal staining for PINCH, but not
in patients with strong staining. Thus, patients with
weak PINCH staining seem to benefit more from adju-
vant chemotherapy than patients with strong staining.
However, these results could not be confirmed in a mul-
tivariate analysis. Taken together, our results indicate
that PINCH could be one factor influencing the prog-
nosis in colorectal cancer patients.
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